- RMTI has an average dollar-volume (as measured by average daily share volume multiplied by share price) of $23.0 million.
- RMTI traded 291,433 shares today in the pre-market hours as of 8:53 AM, representing 11.2% of its average daily volume.
EXCLUSIVE OFFER: Get the inside scoop on opportunities in RMTI with the Ticky from Trade-Ideas. See the FREE profile for RMTI NOW at Trade-Ideas More details on RMTI: Rockwell Medical, Inc. operates as an integrated biopharmaceutical company in the United States and internationally. Currently there are 2 analysts that rate Rockwell Medical a buy, no analysts rate it a sell, and none rate it a hold. The average volume for Rockwell Medical has been 1.2 million shares per day over the past 30 days. Rockwell Medical has a market cap of $221.1 million and is part of the health care sector and drugs industry. The stock has a beta of 1.33 and a short float of 39.2% with 2.26 days to cover. Shares are down 31.2% year to date as of the close of trading on Wednesday. STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more. TheStreetRatings.com Analysis: TheStreet Quant Ratings rates Rockwell Medical as a sell. The company's weaknesses can be seen in multiple areas, such as its disappointing return on equity, poor profit margins, weak operating cash flow, generally disappointing historical performance in the stock itself and generally high debt management risk. Highlights from the ratings report include:
- Return on equity has greatly decreased when compared to its ROE from the same quarter one year prior. This is a signal of major weakness within the corporation. Compared to other companies in the Health Care Equipment & Supplies industry and the overall market, ROCKWELL MEDICAL INC's return on equity significantly trails that of both the industry average and the S&P 500.
- The gross profit margin for ROCKWELL MEDICAL INC is currently extremely low, coming in at 12.60%. It has decreased from the same quarter the previous year. Along with this, the net profit margin of -91.35% is significantly below that of the industry average.
- Net operating cash flow has significantly decreased to -$21.53 million or 232.03% when compared to the same quarter last year. In addition, when comparing to the industry average, the firm's growth rate is much lower.
- The debt-to-equity ratio of 1.16 is relatively high when compared with the industry average, suggesting a need for better debt level management. Despite the company's weak debt-to-equity ratio, the company has managed to keep a very strong quick ratio of 2.71, which shows the ability to cover short-term cash needs.
- RMTI's stock share price has done very poorly compared to where it was a year ago: Despite any rallies, the net result is that it is down by 29.47%, which is also worse that the performance of the S&P 500 Index. Investors have so far failed to pay much attention to the earnings improvements the company has managed to achieve over the last quarter. Naturally, the overall market trend is bound to be a significant factor. However, in one sense, the stock's sharp decline last year is a positive for future investors, making it cheaper (in proportion to its earnings over the past year) than most other stocks in its industry. But due to other concerns, we feel the stock is still not a good buy right now.
- You can view the full Rockwell Medical Ratings Report.
STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. Learn more.